16 articles for JZ Wu
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
Roche Innovation Center Shanghai
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Roche Pharmaceutical Research and Early Development
Design, synthesis, and antiviral activity of adenosine 5'-phosphonate analogues as chain terminators against hepatitis C virus.
Valeant Pharmaceuticals International
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
Nanjing University of Chinese Medicine
Natural products as potential lead compounds to develop new antiviral drugs over the past decade.
Nanjing University of Chinese Medicine
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Nanjing University of Chinese Medicine
Discovery of RORĪ³ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging.
Nanjing University of Chinese Medicine
Identification of novel, selective and potent Chk2 inhibitors.
Valeant Pharmaceutical Research and Development 3300 Hyland Avenue
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
Valeant Pharmaceuticals Research & Development
Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
Valeant Pharmaceutical Research and Development
Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.
Nanjing University of Chinese Medicine
Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase.
Valeant Pharmaceuticals International
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
Roche Innovation Center Shanghai
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
Roche Pharma Research and Early Development
Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors.
Roche Pharma Research and Early Development
